BCHE and Alzheimer disease: The inhibition of butyrylcholinesterase (BChE) was more marked, with a value of 3.50 ± 0.05 mg GALAE/particles, highlighting a potential efficacy of NVs in the more advanced stages of neurodegenerative diseases, such as Alzheimer’s disease, where BChE activity tends to increase.